



DOI: 10.5222/MMJ.2019.08870, Published by Logos Medical Publishing

Ağırca D., Orhan Varoğlu A. Prognostic Importance of Endocan Level in Patients with Ischemic Cerebrovascular Disease. Med Med J. 2019;34(1):1-6

In the published article 'Prognostic Importance of Endocan Level in Patients with Ischemic Cerebrovascular Disease', we inadvertently misstated the number of enrolled patients. Upon careful review of our data, we confirm that this error does not impact the findings or conclusions of our study. We apologize for any confusion this may have caused and provide the correct patient enrollment number below.

1. On page 1, in the abstract section

Original version

'Method: We compared the serum level of endocan of 80 patients and of 60 healthy controls.'

should be corrected as

'Method: We compared the serum level of endocan of 60 patients and of 40 healthy controls.'

2. On page 1, in the özet section

Original version

'Yöntem: Seksen hastanın endokan serum düzeyi ve 60 sağlıklı kontrol karşılaştırıldı.'

should be corrected as

'Yöntem: Altmış hastanın endokan serum düzeyi ve 40 sağlıklı kontrol karşılaştırıldı.'

3. On page 2, in the MATERIAL AND METHOD section

Original version

'This prospective study was performed at Istanbul Medeniyet University University, Neurology Department, between January and June 2015, and contained 80 patients with a diagnosis of cerebrovascular disease. Moreover, 60 age-, and sex-matched individuals who had no neurologic disorder served as the control group.'

should be corrected as

'This prospective study was performed at Istanbul Medeniyet University University, Neurology Department, between January and June 2015, and contained 60 patients with a diagnosis of cerebrovascular disease. Moreover, 40 age-, and sex-matched individuals who had no neurologic disorder served as the control group.'

4. On page 2, in the MATERIAL AND METHOD section

Original version

'As a control group, we selected 60 age-matched participants who had vascular risk factors without any history of stroke, systemic or central nervous system malignancy, recent heart failure and myocardial infarction, and diagnosis of sepsis at the time of the study.'

should be corrected as

'As a control group, we selected 40 age-matched participants who had vascular risk factors without any history of stroke, systemic or central nervous system malignancy, recent heart failure and myocardial infarction, and diagnosis of sepsis at the time of the study.'

5. On page 3, in the RESULTS section

Original version

‘We enrolled 80 patients with acute ischemic cerebrovascular disease with a mean age of 63.85±11.47 years and 60 healthy controls with a mean age of 61.55±12.37 years.’

should be corrected as

‘We enrolled 60 patients with acute ischemic cerebrovascular disease with a mean age of 63.85±11.47 years and 40 healthy controls with a mean age of 61.55±12.37 years.’

6. On page 3, in Table 1

Original version

Table 1. The baseline demographic and laboratory data in patients with ICD and controls.				
		Controls n:60	ICD n:80	P-value
Age		61.55±12.37	63.85±11.47	0.343
Sex	Female	32 / 55.00%	36 / 43.33%	0.253
	Male	28 / 45.00%	44 / 56.67%	
Glucose (mg/dL)		99.71±16.81	124.87±43.7	0.001
Urea (mg/dL)		33.21±9.41	36.03±11.63	0.220
Creatinine (mg/dL)		0.83±0.15	0.86±0.22	0.539
AST (IU/L)		19.57±4.55	18.27±6.69	0.309
ALT (IU/L)		19.29±7.85	16.48±7.56	0.089
Triglycerides (mg/dL)		155.83±85.86	150.4±65.17	0.731
Total cholesterol (mg/dL)		210.28±40.67	197.8±51.73	0.240
HDL cholesterol (mg/dL)		46.92±13.71	43.72±11.35	0.22
LDL cholesterol (mg/dL)		129.78±36.8	126.35±44.03	0.710
WBC (K/uL)		7.24±1.57	8.77±5.19	0.074
RBC (M/uL)		4,75±0.52	4.59±0.59	0.173
HGB (g/dL)		14,23±4,52	13.32±1.73	0.162
Platelet count (K/uL)		243.85±72.95	244±66.61	0.991
TSH (uIU/mL)		1.43±0.89	1.38±1.09	0.846
fT3 (pg/mL)		2.49±0.92	2.79±0.3	0.034
fT4 (ng/dL)		0.96±0.18	0.95±0.13	0.774
HbA1c (%)		5.87±0.64	6.61±1.77	0.116
Insulin		8.11±5.02	13.94±12.36	0.103

Student's t-test was used to compare groups. Data are presented as mean ± standard deviation, *Median (min-max); AST: Aspartate Transaminase, ALT: Alanineaminotransferase, TSH:Thyrotrophin-Stimulating Hormone, fT3:free T3, fT4:free T4, HbA1c: Glycated hemoglobin.

should be corrected as

Table 1. The baseline demographic and laboratory data in patients with ICD and controls.				
		Controls n:40	ICD n:60	P-value
Age		61.55±12.37	63.85±11.47	0.343
Sex	Female	32 / 55.00%	36 / 43.33%	0.253
	Male	28 / 45.00%	44 / 56.67%	
Glucose (mg/dL)		99.71±16.81	124.87±43.7	0.001
Urea (mg/dL)		33.21±9.41	36.03±11.63	0.220
Creatinine (mg/dL)		0.83±0.15	0.86±0.22	0.539
AST (IU/L)		19.57±4.55	18.27±6.69	0.309
ALT (IU/L)		19.29±7.85	16.48±7.56	0.089
Triglycerides (mg/dL)		155.83±85.86	150.4±65.17	0.731
Total cholesterol (mg/dL)		210.28±40.67	197.8±51.73	0.240
HDL cholesterol (mg/dL)		46.92±13.71	43.72±11.35	0.22
LDL cholesterol (mg/dL)		129.78±36.8	126.35±44.03	0.710
WBC (K/uL)		7.24±1.57	8.77±5.19	0.074
RBC (M/uL)		4,75±0.52	4.59±0.59	0.173
HGB (g/dL)		14,23±4,52	13.32±1.73	0.162
Platelet count (K/uL)		243.85±72.95	244±66.61	0.991
TSH (uIU/mL)		1.43±0.89	1.38±1.09	0.846
fT3 (pg/mL)		2.49±0.92	2.79±0.3	0.034
fT4 (ng/dL)		0.96±0.18	0.95±0.13	0.774
HbA1c (%)		5.87±0.64	6.61±1.77	0.116
Insulin		8.11±5.02	13.94±12.36	0.103

Student's t-test was used to compare groups. Data are pre- sented as mean ± standard deviation, *Median (min-max); AST: Aspartate Transaminase, ALT: Alanineaminotransferase, TSH:Thyrotrophin-Stimulating Hormone, fT3:free T3, fT4:free T4, HbA1c: Glycated hemoglobin.

7. On page 3, in Table 2

Original version

Table 2. Comparison of Endocan levels between the patients and the control groups.			
Endocan level (ng/ml)	Controls n:60	ICD n:80	P-value
1 st day	1.47±0.48	1.48±0.6	0.092
7 th day		1.47±0.43	0.093
3 rd month		1.57±0.64	0.361

Student's t-test was used to compare groups.

should be corrected as

Table 2. Comparison of Endocan levels between the patients and the control groups.			
Endocan level (ng/ml)	Controls n:40	ICD n:60	P-value
1 st day	1.47±0.48	1.48±0.6	0.092
7 th day		1.47±0.43	0.093
3 rd month		1.57±0.64	0.361

Student's t-test was used to compare groups.

8. On page 5, after Conclusion, before References, we request that the acknowledgments section be added as follows

'Acknowledgements: We would like to thank Dr. Aybala Erek Toprak for her contributions to obtaining biochemical data and Dr. Abdulkadir Koçer for his contributions to patient collection and the thesis writing process.'